<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38400166</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">183</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12020183</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID has become a central public health concern. This study characterized the effectiveness of BNT162b2 BA.4/5 bivalent COVID-19 vaccine (bivalent) against long COVID symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Symptomatic US adult outpatients testing positive for SARS-CoV-2 were recruited between 2 March and 18 May 2023. Symptoms were assessed longitudinally using a CDC-based symptom questionnaire at Week 4, Month 3, and Month 6 following infection. The odds ratio (OR) of long COVID between vaccination groups was assessed by using mixed-effects logistic models, adjusting for multiple covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At Week 4, among 505 participants, 260 (51%) were vaccinated with bivalent and 245 (49%) were unvaccinated. Mean age was 46.3 years, 70.7% were female, 25.1% had &#x2265;1 comorbidity, 43.0% prior infection, 23.0% reported Nirmatrelvir/Ritonavir use. At Month 6, the bivalent cohort had 41% lower risk of long COVID with &#x2265;3 symptoms (OR: 0.59, 95% CI, 0.36-0.96, <i>p</i> = 0.034) and 37% lower risk of &#x2265;2 symptoms (OR: 0.63, 95% CI, 0.41-0.96, <i>p</i> = 0.030). The bivalent cohort reported fewer and less durable symptoms throughout the six-month follow-up, driven by neurologic and general symptoms, especially fatigue.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with unvaccinated participants, participants vaccinated with the bivalent were associated with approximately 40% lower risk of long COVID and less symptom burden over the six-month study duration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Fusco</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0079-7331</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-7960-4207</Identifier><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI 02895, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Kristen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yehoshua</LastName><ForeName>Alon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CVS Health, Woonsocket, RI 02895, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0009-0005-5089-2873</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jinma</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Santiago M C</ForeName><Initials>SMC</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappelleri</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-9586-0748</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>not available</GrantID><Agency>Pfizer Inc.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BA.4/5</Keyword><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 symptoms</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">bivalent</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>M.D.F., A.Y., M.B.A., K.E.A., T.M.P., L.P., J.R., S.M.C.L. and J.C.C. are employees of Pfizer and may hold stock or stock options of Pfizer. X.S. and A.B. are employees of CVS Health and may hold stock of CVS Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>24</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>24</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>24</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38400166</ArticleId><ArticleId IdType="pmc">PMC10893330</ArticleId><ArticleId IdType="doi">10.3390/vaccines12020183</ArticleId><ArticleId IdType="pii">vaccines12020183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention  Long COVID or Post-COVID Conditions.  [(accessed on 11 December 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Landry M., Bornstein S., Nagaraj N., Sardon G.A., Jr., Castel A., Vyas A., McDonnell K., Agneshwar M., Wilkinson A., Goldman L. Postacute Sequelae of SARS-CoV-2 in University Setting. Emerg. Infect. Dis. 2023;29:519. doi: 10.3201/eid2903.221522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2903.221522</ArticleId><ArticleId IdType="pmc">PMC9973677</ArticleId><ArticleId IdType="pubmed">36703253</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., Safarpour A., Trujillo K.L., Simonson M.D., Green J., Quintana A., Druckman J., Baum M.A. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw. Open. 2022;5:e2238804. doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., Levitan E.B., Levy B., McComsey G.A., McCorkell L., Nadkarni G.N., Parthasarathy S., Singh U., et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329:1934&#x2013;1946. doi: 10.1001/jama.2023.8823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M., Wang R., Yu H., Spatz E.S., Montoy J.C., Rodriguez R., Chang A.M., Elmore J.G., Hannikainen P.A., Hill M. Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. Clin. Infect. Dis. 2023;76:1930&#x2013;1941. doi: 10.1093/cid/ciad045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatz E.S., Gottlieb M., Wisk L.E., Anderson J., Chang A.M., Gentile N.L., Hill M.J., Huebinger R.M., Idris A.H., Kinsman J. Three-Month Symptom Profiles Among Symptomatic Adults with Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Tests: A Prospective Cohort Study from the INSPIRE Group. Clin. Infect. Dis. 2022;76:1559&#x2013;1566. doi: 10.1093/cid/ciac966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac966</ArticleId><ArticleId IdType="pmc">PMC11361781</ArticleId><ArticleId IdType="pubmed">36573005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford N.D., Slaughter D., Edwards D., Dalton A., Perrine C., Vahratian A., Saydah S. Long COVID and Significant Activity Limitation Among Adults, by Age&#x2014;United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:866&#x2013;870. doi: 10.15585/mmwr.mm7232a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a3</ArticleId><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Tebbutt S.J. Long COVID: The next public health crisis is already on its way. Lancet Reg. Health&#x2013;Eur. 2023;28:100612. doi: 10.1016/j.lanepe.2023.100612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100612</ArticleId><ArticleId IdType="pmc">PMC10006728</ArticleId><ArticleId IdType="pubmed">37131860</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V., Gao M., West E.A., Ballouz T., Menges D., Wulf Hanson S., Puhan M.A. Long COVID Through a Public Health Lens: An Umbrella Review. Public. Health Rev. 2022;43:1604501. doi: 10.3389/phrs.2022.1604501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/phrs.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J. Effect of covid-19 vaccination on long covid: Systematic review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., Pozzi C., Mollura M., Mantovani A., Rescigno M. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328:676&#x2013;678. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou G.N., Baraff A., Fox A., Shahoumian T., Hickok A., O&#x2019;Hare A.M., Bohnert A.S., Boyko E.J., Maciejewski M.L., Bowling C.B. Rates and Factors Associated with Documentation of Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System. JAMA Netw. Open. 2022;5:e2224359. doi: 10.1001/jamanetworkopen.2022.24359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.24359</ArticleId><ArticleId IdType="pmc">PMC9338411</ArticleId><ArticleId IdType="pubmed">35904783</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S.  Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose.  [(accessed on 9 September 2023)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.</Citation></Reference><Reference><Citation>Di Fusco M., Sun X., Anatale-Tardiff L., Yehoshua A., Coetzer H., Alvarez M.B., Allen K.E., Porter T.M., Puzniak L., Lopez S.M., et al. Impact of bivalent BA. 4/5 BNT162b2 COVID-19 vaccine on acute symptoms, quality of life, work productivity and activity levels among symptomatic US adults testing positive for SARS-CoV-2 at a national retail pharmacy. Vaccines. 2023;11:1669. doi: 10.3390/vaccines11111669.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111669</ArticleId><ArticleId IdType="pmc">PMC10675533</ArticleId><ArticleId IdType="pubmed">38006001</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegale F., Manica M., Zardini A., Guzzetta G., Marziano V., d&#x2019;Andrea V., Trentini F., Ajelli M., Poletti P., Merler S. Evaluation of Waning of SARS-CoV-2 Vaccine&#x2013;Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw. Open. 2023;6:e2310650. doi: 10.1001/jamanetworkopen.2023.10650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.10650</ArticleId><ArticleId IdType="pmc">PMC10157431</ArticleId><ArticleId IdType="pubmed">37133863</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC/ATSDR Social Vulnerability Index.  [(accessed on 19 December 2023)]; Available online:  https://www.atsdr.cdc.gov/placeandhealth/svi/index.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Symptoms of COVID-19.  [(accessed on 22 August 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.</Citation></Reference><Reference><Citation>Rosner B. Fundamentals of Biostatistics. 8th ed. Cengage Learning; Boston, MA, USA: 2015.</Citation></Reference><Reference><Citation>Freeman G., Halton J.H. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 1951;38:141&#x2013;149. doi: 10.1093/biomet/38.1-2.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/38.1-2.141</ArticleId><ArticleId IdType="pubmed">14848119</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice G.M., Laird N.M., Ware J.H. Applied Longitudinal Analysis. 2nd ed. Volume 998 John Wiley &amp; Sons; Hoboken, NJ, USA: 2011.</Citation></Reference><Reference><Citation>STROBE Statement&#x2014;Checklist of Items That Should Be Included in Reports of Cohort Studies.  [(accessed on 9 September 2023)].  Available online:  https://www.strobe-statement.org/download/strobe-checklist-cohort-studies-pdf.</Citation></Reference><Reference><Citation>Maier H.E., Kowalski-Dobson T., Eckard A., Gherasim C., Manthei D., Meyers A., Davis D., Bakker K., Lindsey K., Chu Z., et al. Reduction in long-COVID symptoms and symptom severity in vaccinated compared to unvaccinated adults. Open Forum Infect. Dis. 2024;11:ofae039. doi: 10.1093/ofid/ofae039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofae039</ArticleId><ArticleId IdType="pmc">PMC10847810</ArticleId><ArticleId IdType="pubmed">38328496</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M., Sun X., Moran M.M., Coetzer H., Zamparo J.M., Alvarez M.B., Puzniak L., Tabak Y.P., Cappelleri J.C. Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron. J. Patient-Rep. Outcomes. 2023;7:77. doi: 10.1186/s41687-023-00616-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-023-00616-5</ArticleId><ArticleId IdType="pmc">PMC10366033</ArticleId><ArticleId IdType="pubmed">37486567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., Debski M., Naing T.K.P., Garg P., Clark A., Ntatsaki E., Vassiliou V.S. Risk factors associated with Post&#x2212; COVID-19 condition: A systematic review and meta-analysis. JAMA Intern. Med. 2023;183:566&#x2013;580. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H., Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790. doi: 10.1016/j.vaccine.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Puzniak L., Hong V., Frankland T.B., Ackerson B.K., Xie F., Takhar H., Ogun O.A., Simmons S., et al. Effectiveness of BNT162b2 BA. 4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: A test-negative case&#x2013;control study. Lancet Respir. Med. 2023;11:1089&#x2013;1100. doi: 10.1016/S2213-2600(23)00306-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00306-5</ArticleId><ArticleId IdType="pubmed">37898148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>